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Summary
Cleidocranial dysplasia (CCD) is a dominantly inherited
disorder characterized by patent fontanelles, wide cra-
nial sutures, hypoplasia of clavicles, short stature, su-
pernumerary teeth, and other skeletal anomalies. We re-
cently demonstrated that mutations in the transcription
factor CBFA1, on chromosome 6p21, are associated
with CCD. We have now analyzed the CBFA1 gene in
42 unrelated patients with CCD. In 18 patients, muta-
tions were detected in the coding region of the CBFA1
gene, including 8 frameshift, 2 nonsense, and 9 missense
mutations, as well as 2 novel polymorphisms. A cluster
of missense mutations at arginine 225 (R225) identifies
this residue as crucial for CBFA1 function. In vitro green
fluorescent protein fusion studies show that R225 mu-
tations interfere with nuclear accumulation of CBFA1
protein. There is no phenotypic difference between pa-
tients with deletions or frameshifts and those with other
intragenic mutations, suggesting that CCD is generally
caused by haploinsufficiency. However, we were able to
extend the CCD phenotypic spectrum. A missense mu-
tation identified in one family with supernumerary teeth
and a radiologically normal skeleton indicates that mu-
tations in CBFA1 can be associated exclusively with a
dental phenotype. In addition, one patient with severe
CCD and a frameshift mutation in codon 402 had os-
teoporosis leading to recurrent bone fractures and sco-
liosis, providing first evidence that CBFA1 may help
maintain adult bone, in addition to its function in bone
development.
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Introduction
Cleidocranial dysplasia (CCD; MIM 119600) is a skel-
etal dysplasia characterized by persistently open or de-
layed closure of sutures, Wormian bones, hypoplastic
and/or aplastic clavicles, wide pubic symphysis, dental
anomalies, and short stature. A number of other radi-
ological and clinical signs are characteristic and should
be sought before diagnosis. The face and skull have a
characteristic appearance with a relatively large cra-
nium, frontal and parietal bossing, and a frontal groove
originating from ossification defects within the metopic
suture. The nose is short and anteverted, and the maxilla
is hypoplastic, giving the impression of midface hypo-
plasia and relative prognathism. Nails and terminal pha-
langes are frequently hypoplastic, and the second meta-
carpal consistently has two ossification centers. Other
radiological changes include a narrow bell-shaped tho-
rax, cervical or missing ribs, characteristic changes in
the pelvis, and large femoral epiphysis (for review, see
Mundlos 1999). The condition is inherited as an auto-
somal dominant trait and was mapped to chromosome
6p21 (Mundlos et al. 1995). Recently, the human
CBFA1 gene was identified as the CCD gene (Lee et al.
1997; Mundlos et al. 1997).
The CBFA1 gene encodes a transcription factor that
is a member of the runt family of proteins (Levanon et
al. 1994). These proteins contain a DNA-binding do-
main highly homologous to the Drosophila pair-rule
gene runt (Nu¨sslein-Volhard and Wieschaus 1980).
CBFA1 contains a region of glutamine and alanine re-
peats in the N-terminal region. Toward the C terminus
is a region rich in proline-serine-threonine (PST), which
is necessary for transcriptional activation of target genes.
The CBFA1 gene consists of eight coding exons and
spans a genomic region of 130 kb (Mundlos et al. 1997;
Geoffroy et al. 1998). Several splice variants have been
described recently (Mundlos et al. 1997; Geoffroy et al.
1998; Xiao et al. 1998).
Whereas the other two members of the mammalian
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Table 1
Primers Used for Polymerase Chain and Sequencing Reactions
Exon Sense Sequence Antisense Sequence
0 AML3E0F TACCCAGCCACCGAGACCAACAGAG AML3E0R GTTTTGCTGACATGGTGTCAC
1 CBFA12 ACTTGTGGCTGTTGTGATGC CBFA17 GCCGCCAAGGCAGGA
2 AML3I1F2 CAGATGCTTGATTCCTGTCGG AML3I2R1 GTGCTGATTTGTATACAGACTAG
3 AML3I2F2 TCATTGCCTCCTTAGAGATGC AML3I3R2 GGACATGAAAGTGACACTAAC
4 AML3I3F1 TATAAAGCAATTTGAAATGCAAGG AML3I4R1 GTTTTGAAGTGAACACATCTCC
5 AML3I4F1 TAAGGCTGCAATGGTTGCTAT AML3I5R1 GTCACTGTGAGCATGGATGAG
6 AML3I5F1 TAGAACATTAGAGCTGGAAGG AML3I6R1 CGGACAGTAACAACCAGACAG
7 AML37F TGTGGCTTGCTGTTCTTTATG AML37R GATACCACTGGGCCACTGCT
Table 2
CBFA1 Mutations Detected in CCD Patients
Patient Codon Nucleotide
No. of
Patientsa Mutation Type
Length of
Predicted
Frameshift
(aa) Referenceb
1 62 186ins(16) 2 Insertion/frameshift 103 This study, 1
2 69 206ArG 1 Polymorphism This study
3 74 222ins(30) 1 Insertion 1
4 L113R 338TrG 1* Missense This study
5 S118R 354CrG 1 Missense This study
6 F121C 362TrG 1 Missense This study
7 C123R 366–367GTrTC 1* Missense This study
8 D161X 481–482delGA 1 Deletion/nonsense 0 This study
9 M175R 524TrG 1 Missense 2
10 180 540–549del(10) 1 Deletion/frameshift 1 1
11 S191N 572GrA 1 Missense 2
12 R193X 577CrT 1 Nonsense This study
13 T205G 614CrG 1 Missense This study
14 R225W 673CrT 1 Missense This study
15 R225Q 674GrA 3 Missense This study
16 274 824delG 1 Deletion/frameshift 32 This study
17 295 887delC 1 Deletion/frameshift 11 This study
18 W297X 891GrA 1 Nonsense 1
19 305 915delC 1 Deletion/frameshift 1 This study
20 376 1127–1128insT 1 Insertion/frameshift 6 This study
21 385 1157delG 1 Deletion/frameshift 97 This study
22 402 1205–1206insC 1 Insertion/frameshift 87 This study
23 495 1379–1380insC 1 Insertion/frameshift 26 This study
24 G511S 1531GrA 1 Missense/polymorphism This study
a An asterisk (*) and a plus sign () denote two mutations identified in a single patient.
b 1 = Mundlos et al. (1997); 2 = Lee et al. (1997)
runt family—Cbfa2 and Cbfa3—are expressed in cells
of hematopoietic origin, the expression of Cbfa1 is re-
stricted to bone and cartilage (Ducy et al. 1997; Otto
et al. 1997; Kim et al. 1999). Cbfa2 is essential for the
initiation of mature-type hematopoiesis (Okuda et al.
1996; Wang et al. 1996). In contrast, Cbfa1 is essential
for the development of osteoblasts from their mesen-
chymal precursors (Ducy et al. 1997). Inactivation of
Cbfa1 in mice by gene targeting leads to a complete
absence of bone. Although the cartilage anlagen develop
normally, there is no differentiation of mesenchymal
stem cells into osteoblasts, no ossification, and no vas-
cular invasion of cartilage (Komori et al. 1997; Otto et
al. 1997). Such mice die shortly after birth because of
impaired respiratory function. Heterozygous Cbfa1 mu-
tant mice display all the hallmarks of CCD, including
open fontanelles and hypoplastic clavicles, but not the
dental anomalies (Huang et al. 1997; Otto et al. 1997).
A radiation-induced mouse mutant exhibiting a CCD
phenotype was shown to harbor a deletion on mouse
chromosome 17, in a region exhibiting conserved syn-
teny to human 6p21, containing the Cbfa1 gene (Otto
et al. 1997).
We have analyzed the coding sequence of the CBFA1
gene in 42 individuals with the clinical diagnosis of
CCD. The purpose of this study was to identify the spec-
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Figure 1 Summary of mutations identified in CCD patients. The bar depicts the CBFA1 protein. Glutamine-alanine repeat (Q/A), DNA
binding runt homology (RUNT), putative NLS, and PST domains are indicated. The TLE corepressor protein interaction motif VWRPY is
shown at the carboxy terminus. AD1–3 and RD denote transcriptional activation and repression domains as described by Thirunavukkarasu
et al. (1998). Mutations are indicated as follows: circle, missense; octogon, nonsense; triangle, insertion; inverted triangle, deletion; and square,
polymorphism.
trum of mutations in CBFA1 in this population and to
determine whether any correlations between phenotype
and genotype could be established.
Subjects and Methods
Patients
Forty-two unrelated families of different ethnic back-
grounds and with the clinical diagnosis of CCD (for
review of diagnostic criteria, see Mundlos 1999) were
included in this study. Informed consent was obtained
from all individuals. DNA was prepared from blood
leukocytes by means of standard procedures.
Mutation Detection
Exons 0–7 of the CBFA1 gene were amplified by PCR
with the primers given in table 1. PCR reactions were
elicited in a total volume of 100 ml, each containing 200
ng DNA, 2 ml dNTP mix at 10 mM each, 0.2 mM each
primer, 10 ml 10 # buffer, and 2.5 U Taq polymerase
(TAQ PCR core kit, Qiagen). For exon 1, DMSO was
added at a final concentration of 10%. Amplification
was done in a thermal cycler (PE 2400, PE Biosystems).
After denaturing at 94C for 4 min, 32 cycles of 94C
for 20 s, 60C for 30 s, and 72C for 30 s were per-
formed. The amplification products were checked by
agarose gel electrophoresis and purified with the PCR
purification kit (Qiagen) according to manufacturer’s in-
structions. Sequencing reactions were performed with 5
ml purified PCR product, 0.2 mM primer, and 4 ml Big
Dye Terminator Cycle sequencing mix with AmpliTaq
DNA polymerase FS (PE Biosystems). Automated se-
quencing was performed on an ABI 377 sequencer. Se-
quences were analyzed by means of ABI View version
1.2.1 software. Every mutation was confirmed by se-
quencing the product of an independent PCR. Restric-
tion digests were performed in those cases where the
mutation introduced a new restriction enzyme site or
abolished a site present in the wild-type DNA. To resolve
ambiguities in the primary sequence, products of an in-
dependent PCR reaction were subcloned by use of the
Original TA Cloning Kit (Invitrogen). On average, a to-
tal of 10 individual clones were sequenced. Base-pair
numbers used refer to GenBank entries AF001443–
AF001450.
Subcellular Localization of Mutant CBFA1 Protein
To transiently express green fluorescent protein fu-
sions, full-length Cbfa1 cDNA (nt 1–1566) and the runt
domain, including the putative nuclear localization sig-
nal (NLS) (nt 304–708), were subcloned into pEGFP-
C1 (Clontech). The mutations R225Q and R225W were
introduced into the resulting plasmids by site-directed
mutagenesis (Sculptor in vitro mutagenesis system,
Amersham Buchler). All plasmids were fully sequenced
to exclude any additional mutations. National Institutes
of Health (NIH) 3T3, C3H 10T1/2, and U2OS cells were
transiently transfected by calcium phosphate coprecip-
itation by means of 30 mg of plasmid DNA per trans-
fection. Fluorescence microscopy was performed on an
Axioplan microscope (Zeiss). Laser-scan micrographs
were taken with a confocal laser scan microscope (410;
Zeiss).
Results
Of the 42 unrelated families investigated for altera-
tions in the coding region of the CBFA1 gene, we were
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Figure 2 Radiological findings in patient F (887delC). A, An-
teroposterior radiograph of the skull showing multiple Wormian bones
in lambdoid and sagittal sutures. B, Chest radiograph demonstrating
cone-shaped thorax, right clavicular hypoplasia, and abnormally
shaped left clavicle with lateral gap. C, Abnormal pelvis with hypo-
plastic iliac wings, reduced pelvic diameter necessitating cesarian sec-
tion, and coxa vara.
able to identify a total of 19 mutations in 18 patients
and an additional 2 polymorphisms. Only one of the
mutations has been described before. With the exception
of mutations affecting codon 225, the mutations were
evenly spread over the entire coding region. Mutations
were detected in all exons except exons 0 and 6 (table
2 and fig. 1).
Missense Mutations
Missense mutations were detected in eight patients. In
four of these, arginine 225 (R225) was mutated; it is
located at the C-terminal end of the runt domain. The
exchange of glutamine for arginine (674GrA [R225Q])
occurred in three unrelated patients. A replacement by
tryptophan (673CrT [R225W]) was identified in one
patient. Both amino acid exchanges abolish the positive
charge of the residue at this position. The high frequency
of mutations affecting R225 identifies this codon as be-
ing either prone to mutagenic events—for example, by
deamination of methyl-C within a CG dinucleotide in
this codon or of important relevance for the normal
function of CBFA1. One patient had two missense mu-
tations within the same exon, separated by 27 bp of
unaltered DNA (see table 2). These mutations convert
both leucine 113 and cystine 123 to arginine residues
(338TrG [L113R] and 366-367GTrTC[C123R]). Both
mutations were passed on from the affected mother to
the daughter and thus are located on the same allele. All
missense mutations identified were located in the runt
domain of CBFA1.
Nonsense Mutations
In addition to the nonsense mutation (891GrA
[W297X]) described in a previous report (Mundlos et
al. 1997), two other nonsense mutations were detect-
ed. A 2-bp deletion resulting in a stop codon (481–
482delGA [D161X]) was identified in a family with three
affected generations. The other mutation is predicted to
result in a truncated protein, including the amino-ter-
minal part of the runt domain. The 577CrT (R193X)
mutation was passed on to the patient from his father,
whose parents were unaffected.
Deletions and Insertions
Deletions were identified in five patients. Single base-
pair deletions with subsequent frameshifts occurred in
four patients. Whereas one patient (1157delG) had
healthy parents, the other mutations were passed on for
several generations. Radiographs of patient F (887delC)
are shown in figure 2. The predicted proteins contain
the entire runt domain.
Single base-pair insertions were found in three pa-
tients. In one patient, part of the CAG repeat within
exon 1 was extended by 16 nucleotides. This mutation
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Figure 3 Radiological findings in patient C. A, Anteroposterior
radiograph of patient C, carrying the mutation 1205insC. The chest
is severely deformed because of compression fractures of the thoracic
vertebrae and the subsequent development of a kyphoscoliosis. A Har-
rington rod was implanted for stabilization. Both clavicles are absent.
The lumbar vertebrae have an irregular structure, are severely osteo-
penic, and are partially collapsed. The entire skeleton is extremely
osteopenic, giving an almost radiotranslucent appearance especially of
the ribs and the thoracic spine. The iliac wings are hypoplastic. B,
Radiograph of the left hand and the distal part of the radius and the
ulna of patient C. Note severe osteoporosis and greatly reduced tra-
becular and cortical bone. There is also hypoplasia of the terminal
phalanges.
is identical to the one characterized in our previous re-
port (Mundlos et al. 1997), describing an unrelated pa-
tient. A 2-bp deletion (481–482delGA [D161X]) is de-
tailed in the Nonsense Mutations subsection, above.
Polymorphisms
Two novel polymorphisms were identified. An ArG
transition (206GrA, silent) within the Q/A domain was
found on one allele in patient A, whose healthy mother
carried the transition on both alleles.
Patient B had two mutations within the coding region
of the CBFA1 gene. The missense mutation 362TrG
(F121C) was inherited from the mother. The healthy
father of a patient carried a GrS change at position 511
(1531GrA [G511S]) that was passed on to patient B.
Of interest, the mother and grandfather of the patient
had very mild phenotypes, with supernumerary teeth but
no clavicular involvement. Chest, skull, and pelvic ra-
diographs showed none of the changes classically ob-
served in CCD. In contrast, patient B had a one-sided
pseudarthrosis of the clavicle and typical facial appear-
ance. Thus, one might assume that the simultaneous
occurrence of two mutations led to the typical CCD
phenotype, although either one by itself produced a phe-
notype that was weak (in the case of the mother) or not
discernible (in the case of the father). However, intra-
familial variation in expressivity, which is a common
feature in CCD, may serve as an alternative explanation
for the more-severe phenotype of patient B, with G551S
being a polymorphism.
Genotype-Phenotype Correlation
To evaluate the functional significance of the muta-
tions identified, we undertook a careful evaluation of
phenotypes and compared them with the different types
of mutations observed. Patients were evaluated for cla-
vicular involvement, open fontanelles, presence of su-
pernumerary teeth (if applicable), and height. Although
penetrance was 100% in our cases, intrafamilial varia-
tion in expressivity was common. With the exception of
the family discussed above, clavicular involvement was
invariably present but was frequently confined to the
most distal part of the clavicle, giving an almost normal
impression upon inspection. The number and presence
of supernumerary teeth was highly variable and did not
correlate with the rest of the phenotype. In summary,
we were not able to identify any significant genotype-
phenotype correlation. Also, there was no difference in
severity of phenotypes among patients with identified
mutations and those in whom no mutations in CBFA1
had been found. However, the identification of muta-
tions in patients with less-typical phenotypes allowed us
to redefine the phenotypic spectrum of CCD.
Nonsense or frameshift mutations within or 5′ of the
runt domain are expected to result in a truncated protein
without DNA binding domain and thus without func-
tion. In contrast, premature stop codons 3′ of the runt
domain coding region could have antagonistic effects,
leading to a truncated protein that binds DNA but has
no activation potential. Depending on the stability of
mRNA and protein, such mutations could have a dom-
inant negative effect. Therefore, we were particularly
interested in mutations affecting the last exon and thus
having a greater probability of giving rise to a stable
mRNA product. We identified a total of four mutations
Figure 4 Subcellular localization of mutant CBFA1. Fluorescence (left), visible-light (right), and double-projection (middle) micrographs
of CBFA1-GFP fusion proteins expressed in NIH 3T3 cells. Note the different subcellular localization of control GFP (A), wild-type CBFA1
(B), and mutant R225Q CBFA1 (C).
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Figure 5 Subcellular localization of runt domain-GFP fusion protein in NIH 3T3 cells. Laser-scan micrographs show the intracellular
distribution of control GFP (A), wild-type CBFA1-runt (B), R225Q (C), and R225W (D) mutant CBFA1-runt proteins.
in this part of the gene. The patients with the mutation
1205–1206insC and 1379–1380insC are remarkable in
that they represent the extremely severe and the mild
ends of the phenotypic spectrum, respectively.
Because of his unusual clinical features, patient C
(with the mutation 1205–1206insC) is of particular in-
terest. Patient C is the offspring of healthy parents. On
a radiograph taken in utero, a transverse fracture of the
left femur was noted. X-rays taken 2 days after birth
demonstrated greenstick fractures of the tibia and fibula
bilaterally. At birth, the skull was almost unossified, both
clavicles were absent, and distal hypoplasia of phalanges
with partial absence of the nails was noted. On the basis
of these observations, the preliminary diagnosis of CCD
was made. During childhood and adolescence, a total
of nine fractures of long bones occurred after minor
trauma. The patient developed a pseudarthrosis after a
fracture of the femur with lack of callus formation, ne-
cessitating fixation with an intramedullary nail. The pa-
tient suffers from partial deafness due to conduction
hearing impairment. A number of supernumerary teeth
were extracted. Progressive severe scoliosis and lordosis
of the spine developed, necessitating the implantation of
a Harrington rod for spinal support (fig. 3). At the age
of 23 years, patient C had a body height of 129 cm.
The long bones of both legs display increasing bending
toward the midline. X-rays taken during childhood and
adolescence demonstrated severe osteoporosis as the
cause of the recurrent fractures and the spinal deformity.
DEXA scans performed at the age of 24 years revealed
an extreme form of osteoporosis, with3.8 for the lum-
bar spine (L2/L3), 6.09 for the hip, and 6.34 for the
left forearm. (Values are SDs, with 0 representing the
mean for age and sex. Values !1.5 represent
osteopenia.)
In contrast, patient D exhibited a very mild phenotype.
He was brought to medical attention only because of
supernumerary teeth. His mutation, 1379–1380insC,
causes a frameshift at the very 3′ end of the coding re-
gion, leaving the runt domain, the NLS, and putative
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activation domains intact, but inactivating the valine-
tryptophan-arginine-proline-tyrosine (VWRPY) f,
a region suspected to interact with the transducin-like
enhancer of split (TLE) family of transcriptional co-
repressors. Patient D is of normal height and excellent
physical health. The clinical signs of CCD are restricted
to a gap in the most lateral part of the clavicle bilaterally
and supernumerary teeth.
Subcellular Localization of NLS Mutant CBFA1 Protein
The amino acid R225, which was the residue most
frequently affected by mutations in our series, resides
within a stretch of basic amino acids at the carboxy
terminus of the runt domain. Since NLSs necessary for
the function of transcription factors usually contain a
number of basic residues, we suspected that R225 mu-
tations might affect the subcellular distribution of
CBFA1. To test this hypothesis, we constructed fusion
proteins between green fluorescent protein and CBFA1.
The constructs were transiently transfected into human
osteosarcoma U2OS, mouse fibroblast NIH 3T3, and
mesenchymal stem cell C3H 10T1/2 lines. Similar results
were obtained with all three cell lines. In contrast to a
GFP control, which was evenly distributed throughout
cytoplasm and nucleus, CBFA1-GFP fusion protein was
detected exclusively in the nucleus (fig. 4). Similar results
were obtained when the runt domain of CBFA1, in-
cluding the putative NLS, was expressed as GFP fusion
(fig. 5). Thus, amino acids 102–236 were sufficient to
control nuclear accumulation of CBFA1.
When glutamine (R225Q) or tryptophan (R225W)
was substituted for R225, CBFA1 was unable to quan-
titatively accumulate in the nucleus. The intracellular
distribution pattern of mutated CBFA1, as well as iso-
lated runt/NLS, was indistinguishable from GFP control
(fig. 4 and 5). Thus, mutations in R225 completely abol-
ish the function of the NLS in accumulating CBFA1 in
the nucleus.
Discussion
Mutations inCBFA1, a transcription factor of the runt
family, have been identified as a cause of the autosomal
dominant skeletal disorder CCD (Lee et al. 1997; Mund-
los et al. 1997). In the present study, we have identified
new mutations in 18 unrelated families of different eth-
nic backgrounds. All of the identified mutations were
unique, except for those in three patients who had the
same 674GrA (R225Q) mutation and in patient E, who
had a 16-bp insertion at bp 186 of exon 1. The latter
mutation is identical to a mutation in an unrelated pa-
tient described in our earlier report (Mundlos et al.
1997). An imperfect 69-bp GAG repeat exists at this site
in exon 1, with both patients having insertions of small
parts of the repeat sequence. The existence of these re-
petitive sequences may predispose this site to errors dur-
ing recombination or DNA replication and may account
for the recurrent insertion seen in these two unrelated
patients.
The mutations identified in this study were evenly dis-
tributed along the coding region of CBFA1. No muta-
tions were found in exons 0 and 6, perhaps because of
their small size. However, an alternative splice product
containing all exons but exon 6 has been identified
(Mundlos et al. 1997). Thus, exon 6 might be dispen-
sable for CBFA1 function, and mutations involving exon
6 might not produce a phenotype. Likewise, the func-
tional significance of exon 0, although expressed in os-
teoblasts, remains unknown, since alternative start sites
are likely to exist (Mundlos et al. 1997). Genetic het-
erogeneity is a possible explanation for the relatively low
frequency of mutations detected in this study. However,
all CCD families tested so far map to the 6p21 locus.
Other explanations are mutations within yet unknown
regulatory sequences or smaller deletions involving sin-
gle exons. Deletion testing with YACs from the critical
region in 10 patients without identifiable mutations re-
vealed no deletion (C. Mundlos, unpublished data), in-
dicating that large genomic deletions, as described by
Mundlos et al. (1997), are not a common feature of
CCD.
For CBFA1, as well as for the closely related tran-
scription factor CBFA2, a number of functional domains
have been defined (Kanno et al. 1998; Thirunavukkarasu
et al. 1998). CBFA1 contains an amino-terminal stretch
of polyglutamine and polyalanine repeats (Q/A domain),
followed by the DNA-binding runt homology domain
and the carboxy-terminal PST-rich domain. The PST do-
main consists of two subdomains, the amino terminal
having transactivating capabilities and the carboxy ter-
minal being able to repress transactivation. A short
stretch of amino acids between runt homology and PST
domains is responsible for nuclear localization of the
CBFA1 protein. The carboxy terminus of CBFA1 con-
sists of the VWRPY motif that is conserved in all runt
homology proteins in every species analyzed so far. Its
function might be to bind the corepressor proteins of
the TLE/Grg family homologous to Drosophila groucho
(Stifani et al. 1992).
The identification of a number of nonsense and frame-
shift mutations in this study poses the question of
whether the predicted proteins derived from the mutant
alleles have a function of their own. With the exception
of one patient, however, the phenotypes of all patients
analyzed were within the range of variation known to
occur in CCD, and no systematic effect relating the
length of the hypothetical truncated protein to the se-
verity of the clinical features was seen. Thus it seems
reasonable to conclude that these mutations cause func-
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tional haploinsufficiency. Truncated proteins may be un-
stable in the cellular environment and can be degraded
rapidly (Akeson et al. 1989; Hashimoto et al. 1996).
Moreover, there are examples of instability and altered
nuclear export of mRNA derived from mutant alleles
(Redford-Badwal et al. 1996). Thus it may be speculated
that the predicted protein products are not present in
adequate levels to produce distinguishable effects that
exceed the effect caused by the mere absence of one copy
of the CBFA1 gene.
One possible exception to this is the frameshift mu-
tation in codon 402 (patient C). The protein product of
this allele is predicted to contain the first 401 amino
acids of CBFA1, followed by 87 additional novel amino
acids. The patient carrying this mutation exhibits fea-
tures beyond the spectrum typically seen in CCD. In
addition to the classical features of CCD, which are re-
markably severe, bone fragility and severe osteoporosis
are present—findings not generally considered part of
the CCD spectrum. The presence of intrauterine bone
fractures indicates a congenital defect in bone stability.
X-rays and DEXA scans of the spine and radius revealed
an extreme form of bone loss. Cortical bone was very
thin and undermineralized, whereas trabecular bone was
dramatically reduced and almost absent in some parts.
This form of bone loss is indistinguishable from other
forms of osteoporosis and explains the recurrent frac-
tures and the spinal deformity observed in this patient.
Mice carrying one mutated Cbfa1 allele show all the
hallmarks of CCD. When both copies of the Cbfa1 gene
are inactivated, bone development cannot proceed, be-
cause of a block in differentiation of mesenchymal pre-
cursor cells toward osteoblasts (Komori et al. 1997; Otto
et al. 1997). The phenotype exhibited by patient C could
be an intermediate form between these two extremes.
Retarded osteoblast differentiation and/or the produc-
tion of a lower number of osteoblasts from precursor
cells leading to an overall reduced bone mass could ex-
plain this exceptional phenotype. The mutated protein
containing the DNA binding domain, but not the trans-
activation domains, might act as a dominant negative
form of CBFA1 by binding to the consensus binding site
on target gene promoters without being able to trans-
activate or repress. An alternative explanation is the pos-
sibility that the 87 novel amino acids appended to the
carboxy terminus provide novel repressive properties to
the CBFA1 protein. In either case, the wild-type protein
transcribed from the second allele will not be able to
access these promoters at the same rate as in patients in
whom one allele is effectively inactivated. If this con-
clusion is correct, one would expect CBFA1 to play a
role not only during embryonic development, but also
during bone remodeling in adulthood. This is likely,
since bone is continuously renewed by differentiation of
marrow precursor cells into osteoblasts and the subse-
quent production of new bone matrix. As in early de-
velopment, CBFA1 is likely to be the rate-controlling
factor in this differentiation process. This conclusion is
supported by the observation that transgenic mice over-
expressing a dominant negative form of Cbfa1 develop
an osteopenic phenotype (Ducy et al. 1999). Haploin-
sufficiency, however, seems not to be sufficient to reduce
bone mass, as first preliminary DEXA scan experiments
in a small number of CCD patients have shown (S.
Mundlos, unpublished data). Since patient C has unaf-
fected parents and no children, a modification of the
CCD phenotype by an additional mutation in another
bone-related gene cannot be excluded. In either case, the
data identify CBFA1 as a gene involved not only in skel-
etal development and growth but also in the regulation
of bone mass.
The missense mutations identified in this study
showed an obvious clustering at R225. R225 resides
within an area of the CBFA1 protein thought to be re-
sponsible for nuclear localization. Whereas Thirunavuk-
karasu et al. (1998) describe a myc-related NLS in
CBFA1 starting three amino acids carboxy-terminal to
R225 and not including this residue, Kanno et al. (1998)
identify an NLS in a region of CBFA2 with sequence
identity to CBFA1, which contains R225 as one of six
basic amino acids crucial for nuclear import. To test
whether R225 is indeed a functional part of an NLS, we
analyzed the subcellular distribution of CBFA1-GFP fu-
sion proteins after transient transfection into different
cell lines. There was no apparent difference in intracel-
lular distribution between CBFA1 and the isolated runt
domain. Thus, the nuclear matrix–targeting signal lo-
cated in the carboxy-terminal region of CBFA1 does not
seem to influence nuclear accumulation (Lindenmuth et
al. 1997; Thirunavukkarasu et al. 1998). Both muta-
tions—R225Q and R225W—completely abolished the
function of the NLS, rendering the protein unable to
quantitatively accumulate in the nucleus. Although our
in vitro data may only qualitatively reflect the in vivo
situation in the respective CCD patients because of un-
physiologically high intracellular protein levels in tran-
sient transfection assays, these results suggest that a lack
of nuclear CBFA1 accumulation is the cause of haploin-
sufficiency in these cases. This finding represents a novel
mechanism by which mutations can lead to a disease
phenotype.
All missense mutations identified reside within either
the NLS or the DNA-binding runt homology domain.
It is possible that the latter abolish DNA-binding ability
of the transcription factor CBFA1. On the other hand,
the runt homology domain is responsible for heterodi-
merization with Cbfb, a cofactor that enhances the af-
finity of the a subunit to DNA (Kagoshima et al. 1996).
Although Thirunavukkarasu et al. (1998) show in vitro
evidence that the QA domain prevents binding of CBFb
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to CBFA1, this might not necessarily be true for the in
vivo situation. There is a high degree of sequence ho-
mology between the DNA binding domains of the mam-
malian members of the runt homology family of proteins
and the Drosophila transcription factors runt and loz-
enge. The evolutionary conservation in this protein do-
main indicates that only a small degree of sequence var-
iation is allowed when function is to be retained. Thus,
a high percentage of missense mutations involving the
runt domain is likely to affect protein function and lead
to haploinsufficiency. Further collection of mutation
data of CBFA1, their analysis with the use of in vitro
studies, and the determination of the three-dimensional
structure of CBFA1 will contribute to a better under-
standing of the function of this protein.
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